Delving into the Latest Updates on LSCD101 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Autologous Limbal Epithelial Cell Transplantation

Target-

Action-

Mechanism-

Therapeutic Areas

Eye DiseasesOther Diseases

Active Indication-

Inactive Indication

Arcus SenilisLimbal stem cell deficiency

Originator Organization

CLIPS SA

Active Organization-

Inactive Organization

CLIPS SA

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Clinical Study Objective:
To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency
Study Method:
Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.

Start Date31 Jan 2020

Sponsor / Collaborator

CLIPS SA

KCT0004741

/ CompletedPhase 1

Phase I Study to Evaluate Safety of LSCD101(Cultured Autologous Limbal Epithelial Cell Sheet) Transplantation for Limbal Stem Cell Deficiency

Start Date31 Jan 2020

Sponsor / Collaborator

CLIPS SA

100 Clinical Results associated with LSCD101

Login to view more data

100 Translational Medicine associated with LSCD101